Trevi Therapeutics TRVI
$13.35 −$0.37 (-2.70%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $13.35 0.00%
Open$13.58
Prev close$13.72
Day range$13.23 – $13.90
Volume2.09M
Market cap$1.90B
P/E (TTM)–
Dividend yield–
TRVI Stock News
Headlines matching Trevi Therapeutics or the TRVI ticker, most recent first.
- Trevi Therapeutics (TRVI) Receives a Buy From H.C. Wainwright
- H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
- A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40
- Trevi Therapeutics (TRVI) Receives a New Rating From B. Riley Securities
- Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 Positive
- Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30
- Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 Positive
- JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $28 Positive
- Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
- BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36
- BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36
- H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24 Positive
- Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
- Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29 Positive
- H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21
No comments yet — be the first to weigh in on TRVI.
Sign in to join the discussion.